TG Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Yahoo! Finance
TG Therapeutics (NASDAQ:TGTX) executives highlighted rapid revenue growth for BRIUMVI in 2025, expanding adoption in relapsing multiple sclerosis (RMS), and multiple upcoming clinical and regulatory catalysts during the company's fourth-quarter and year-end 2025 earnings call. BRIUMVI revenue growth and 2026 outlook Chairman and CEO Michael Weiss said 2025 was a “defining year,” with the company delivering approximately $616 million in total global revenue . The “vast majority” came from $594 million of BRIUMVI U.S. net sales , capped by a fourth quarter of $183 million . Weiss characterized the fourth-quarter performance as approximately 92% year-over-year growth and 20% sequential growth versus the third quarter, attributing the results to physician choice, patient persistence, and rising confidence in the product. ? SoundHound's New Sales Assist Agent Put Voice AI Back in the Spotlight TG Therapeutics Stock 300% Rally Has Legs Yet Chief Commercial Officer Adam Waldman re
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual MeetingGlobeNewswire
- TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook [Seeking Alpha]Seeking Alpha
- A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics concludes enrolment in Phase III Briumvi trial [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI [Yahoo! Finance]Yahoo! Finance
TGTX
Earnings
- 2/26/26 - Miss
TGTX
Analyst Actions
- 2/2/26 - JP Morgan
TGTX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- 2/27/26 - Form 10-K
- TGTX's page on the SEC website